ArticleDEN open2027
Clinical Utility of Anti-reflux Mucosal Intervention for Refractory Gastroesophageal Reflux Disease in Patients With a Hiatal Hernia.
Article in DEN open, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surgical fundoplication is the standard treatment for refractory gastroesophageal reflux disease (GERD) with large (≥3 cm) hiatal hernias; however, its invasiveness is problematic in older adults and high-risk patients. Anti-reflux mucosal intervention (ARMI) is a less invasive endoscopic alternative; however, patients with large hernias have previously been excluded from studies, limiting available evidence. We assessed the feasibility, short-term clinical outcomes, and safety of ARMI in this population. Methods: We retrospectively analyzed consecutive patients with proton pump inhibitor (PPI)/potassium-competitive acid blocker (P-CAB)-refractory GERD and sliding hiatal hernias ≥3 cm who underwent ARMI (anti-reflux mucosectomy; anti-reflux mucoplasty) between April 2024 and April 2025. GERD-Health-Related Quality of Life (GERD-HRQL), GERD Questionnaire (GerdQ), and Frequency Scale for the Symptoms of GERD (FSSG) scores were compared before ARMI and 3 months afterward. PPI/P-CAB discontinuation and treatment-related adverse events were also assessed. Results: Ten patients (mean age 74.3 years; 80% women; hernia size 3-6 cm) were included, all with American Society of Anesthesiologists physical status ≥ II. At 3 months, mean GERD-HRQL scores decreased from 21.1 to 4.6 ( Conclusions: ARMI was technically feasible, showed favorable short-term outcomes in patients with refractory GERD and 3-6-cm hiatal hernias, and may represent a less invasive option for older or high-risk patients. Trial Registration: N/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.